Brief: Sonnet Biotherapeutics Announces Pharmacokinetic and Pharmacodynamic Data In A Phase 1 Dose-Escalation Trial Of Son-1010

Sonnet Biotherapeutics Holdings

19/01/2023 13:26

Jan 19 (Reuters) - Sonnet Biotherapeutics Holdings Inc
 SONN.O :
    * SONNET BIOTHERAPEUTICS ANNOUNCES PHARMACOKINETIC AND
PHARMACODYNAMIC DATA IN A PHASE 1 DOSE-ESCALATION TRIAL OF
SON-1010
    * SONNET BIOTHERAPEUTICS HOLDINGS INC - PK DATA SHOWS AN
EXTENDED
HALF-LIFE OF SON-1010 OF APPROXIMATELY 112 HOURS, COMPARED TO 12
HOURS FOR RHIL-12
    * SONNET BIOTHERAPEUTICS HOLDINGS - 24 VOLUNTEERS DOSED IN
STUDY
SB102 TO ASSESS SAFETY, PK, AND PD OF SON-1010 WITHOUT
BACKGROUND OF PRIOR CHEMOTHERAPY
    * SONNET BIOTHERAPEUTICS - SAFETY REVIEW COMMITTEE HAS FOUND
NO
SIGNIFICANT SAFETY CONCERNS TO DATE AND HAS APPROVED ADVANCING
TO EACH HIGHER DOSE LEVEL
    * SONNET BIOTHERAPEUTICS- SIMULATION OF CONTROLLED,
PROLONGED
INDUCTION OF IFNΓ, MINIMAL RELATED ADVERSE EVENTS SUGGEST THAT
DOSE ESCALATION CAN CONTINU

Further company coverage:  SONN.O 
 ((Reuters.Briefs@thomsonreuters.com;))